Other News To Note
Friday, April 15, 2011
Regulus Therapeutics Inc., of La Jolla, Calif., said it is collaborating with researchers at the University of California, San Diego (UCSD) School of Medicine seeking treatments for angiogenic diseases using microRNA therapeutics. The company said that the research will combine Regulus' microRNA platform with UCSD's expertise in animal models of angiogenesis to discover anti-angiogenic microRNA-targeted therapies. Angiogenesis, which is the formation of new blood vessels, contributes to the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.